Field-Template, QSAR, Ensemble Molecular Docking, and 3D-RISM Solvation Studies Expose Potential of FDA-Approved Marine Drugs as SARS-CoVID-2 Main Protease Inhibitors
Open Access
Abstract
Currently, SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) has infected people among all countries and is a pandemic as declared by the World Health Organization (WHO). SARS-CoVID-2 main protease is one of the therapeutic drug targets that has been shown to reduce virus replication, and its high-resolution 3D structures in complex with inhibitors have been solved. Previously, we had demonstrated the potential of natural compounds such as serine protease inhibitors eventually leading us to hypothesize that FDA-approved marine drugs have the potential to inhibit the biological activity of SARS-CoV-2 main protease. Initially, field-template and structure–activity atlas models were constructed to understand and explain the molecular features responsible for SARS-CoVID-2 main protease inhibitors, which revealed that Eribulin Mesylate, Plitidepsin, and Trabectedin possess similar characteristics related to SARS-CoVID-2 main protease inhibitors. Later, protein–ligand interactions are studied using ensemble molecular-docking simulations that revealed that marine drugs bind at the active site of the main protease. The three-dimensional reference interaction site model (3D-RISM) studies show that marine drugs displace water molecules at the active site, and interactions observed are favorable. These computational studies eventually paved an interest in further in vitro studies. Finally, these findings are new and indeed provide insights into the role of FDA-approved marine drugs, which are already in clinical use for cancer treatment as a potential alternative to prevent and treat infected people with SARS-CoV-2.Keywords
This publication has 38 references indexed in Scilit:
- Analysis of Biomolecular Solvation Sites by 3D-RISM TheoryThe Journal of Physical Chemistry B, 2013
- Ligand Mapping on Protein Surfaces by the 3D-RISM Theory: Toward Computational Fragment-Based Drug DesignJournal of the American Chemical Society, 2009
- ChemInform Abstract: Lead Finder: An Approach to Improve Accuracy of Protein—Ligand Docking, Binding Energy Estimation, and Virtual Screening.ChemInform, 2009
- Validation of Molecular Docking Programs for Virtual Screening against Dihydropteroate SynthaseJournal of Chemical Information and Modeling, 2009
- Computer-aided drug discovery and development (CADDD): In silico-chemico-biological approachChemico-Biological Interactions, 2008
- Molecular field technology applied to virtual screening and finding the bioactive conformationExpert Opinion on Drug Discovery, 2007
- Ensemble docking of multiple protein structures: Considering protein structural variations in molecular dockingProteins: Structure, Function, and Bioinformatics, 2006
- Flexible protein–protein dockingCurrent Opinion in Structural Biology, 2006
- Molecular Field Extrema as Descriptors of Biological Activity: Definition and ValidationJournal of Chemical Information and Modeling, 2006
- Introducing ONETEP: Linear-scaling density functional simulations on parallel computersThe Journal of Chemical Physics, 2005